For how we live.
In a 200-patient prospective validation, a DNA-methylation assay reached an AUC of 0.91 and, by one analysis, could have averted about 55% of unnecessary biopsies without missing significant cancers.
In the French GETUG AFU 18 trial an 80 Gy dose beat the standard 70 Gy on 10-year progression-free survival (83.6% vs 72.2%), but the advantage at the prespecified 5-year mark was far smaller.
The large trials built to confirm vitamin E's promise came back null, and a meta-analysis tied 400 IU a day or more to a small rise in all-cause mortality.
Men who carry a BRCA2 mutation develop prostate cancer earlier and in more aggressive forms. Trial evidence now supports offering them PSA screening from 40; the case for BRCA1 carriers is weaker.
US mortality is roughly two-fold higher in Black men, but when care and treatment are equal — in the military health system and in trials — the stage-for-stage survival gap largely disappears.
A small 1990s trial hinted selenium supplements cut cancer, launching a supplement boom. The much larger SELECT trial found no benefit — and signals of harm, including more type 2 diabetes.
A fear that shaped urology for decades held that raising testosterone feeds prostate cancer. Randomised trials and a large 2024 safety analysis find no such rise in screened men.
In the ProtecT trial's patient-reported data, surgery hit urinary control and erections hardest and radiotherapy the bowel, while monitoring let function fade slowly. Cancer deaths were the same.
European screening cut prostate-cancer deaths by 21% at 13 years, at the cost of overdiagnosis; a UK trial of a single test found no mortality benefit. US guidance now makes it a personal choice for men 55 to 69.
Modern techniques fail less than 1% of the time. The best meta-analysis found no link to aggressive or fatal prostate cancer; a 2-million-man registry still sees a small excess, most likely from extra testing.
In the 500-man PRECISION trial, MRI-guided biopsy detected clinically significant cancer in 38% of men versus 26% with the old blind biopsy — and spared 28% a biopsy altogether.
Registries show a real but narrow signal: a few cancers, led by prostate and thyroid, run high in 9/11 responders, while overall cancer incidence sits at or below the rate expected.
US guidance recommends mammography from 40. A Canadian review of the same randomised evidence put the benefit at 0.27 fewer breast cancer deaths per 1,000 women aged 40-49 over ten years.
Five-fraction SBRT improved several quality-of-life measures but was not superior to longer IMRT for prostate cancer. Three-year disease-free survival was 88.6% with SBRT and 92.1% with IMRT.
In a trial of 1,643 men, prostate cancer killed 3.1% of the monitored group and 2.2% of the surgery group — a difference the trial could not distinguish from chance. Metastases were twice as common.
The radioligand cut the risk of radiographic progression or death by 28% when added to standard therapy in a phase 3 trial — a real but incremental gain, bought with more side-effects.
That is the 23-year result from the largest randomised trial. A 2026 Cochrane review of 789,086 men rates the mortality benefit moderate-certainty and the harms largely unmeasured.
A review of Paige Prostate Detect and Ibex Prostate Detect finds the tools mainly help less-specialized pathologists, and warns performance shifts when a tool meets a new population.
A linked-registry cohort of New South Wales residents from 2001 to 2018 finds cancer risk in people with intellectual disability inverts with age — higher when young, lower after 50.
In the phase 3 PATCH trial, oestrogen skin patches were non-inferior to LHRH injections for three-year metastasis-free survival, with fewer hot flushes but more breast swelling.
A trial across five Chinese hospitals found remote robotic urological surgery non-inferior to local surgery. The sample is small, the surgeons were experts, and the network never failed.
In 105,260 people followed for 7.6 years, higher intakes of sorbates, sulfites, nitrates and acetates tracked with modestly higher cancer incidence. This is an observational study of self-reported diets.
A draft-reporting model cut documentation time 15.5% across 23,960 radiographs without changing report quality. A separate reader study found AI assistance raised prostate MRI accuracy by 3.3 percentage points.